Figure 1
Expression of FcγRs on monocytes from ITP patients before or after therapy and from healthy controls. (A) Representative scattergrams of surface expression of FcγRIII/CD16, FcγRII/CD32, and FcγRI/CD64 on CD14+ monocytes from a healthy control and an ITP patient before HD-DXM therapy. CD14+ monocytes were gated based on their forward/sideward scatter. (B-D) Expression (MFI) of FcγRI/CD64 (B), FcγRII/CD32 (C), and FcγRIII/CD16 (D) on monocytes from ITP patients before and after HD-DXM therapy and from healthy controls. Significance among patients before and after HD-DXM therapy and healthy groups was determined by ANOVA, and differences between 2 groups were compared by Student-Newman-Keuls test. Bars represent SD *P < .001.

Expression of FcγRs on monocytes from ITP patients before or after therapy and from healthy controls. (A) Representative scattergrams of surface expression of FcγRIII/CD16, FcγRII/CD32, and FcγRI/CD64 on CD14+ monocytes from a healthy control and an ITP patient before HD-DXM therapy. CD14+ monocytes were gated based on their forward/sideward scatter. (B-D) Expression (MFI) of FcγRI/CD64 (B), FcγRII/CD32 (C), and FcγRIII/CD16 (D) on monocytes from ITP patients before and after HD-DXM therapy and from healthy controls. Significance among patients before and after HD-DXM therapy and healthy groups was determined by ANOVA, and differences between 2 groups were compared by Student-Newman-Keuls test. Bars represent SD *P < .001.

Close Modal

or Create an Account

Close Modal
Close Modal